N
Nagahiro Saijo
Researcher at AstraZeneca
Publications - 386
Citations - 31129
Nagahiro Saijo is an academic researcher from AstraZeneca. The author has contributed to research in topics: Lung cancer & Chemotherapy. The author has an hindex of 65, co-authored 386 publications receiving 28187 citations. Previous affiliations of Nagahiro Saijo include Harvard University.
Papers
More filters
Journal ArticleDOI
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Tony Mok,Yi-Long Wu,Sumitra Thongprasert,Chih-Hsin Yang,Da Tong Chu,Nagahiro Saijo,Patrapim Sunpaweravong,Baohui Han,Benjamin Margono,Benjamin Margono,Yukito Ichinose,Yutaka Nishiwaki,Yuichiro Ohe,Jin Ji Yang,Busyamas Chewaskulyong,Haiyi Jiang,Emma Duffield,Claire Watkins,Alison Armour,Masahiro Fukuoka +19 more
TL;DR: Gefit inib is superior to carboplatin-paclitaxel as an initial treatment for pulmonary adenocarcinoma among nonsmokers or former light smokers in East Asia and the presence in the tumor of a mutation of the EGFR gene is a strong predictor of a better outcome with gefitinib.
Journal ArticleDOI
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
William D. Travis,Elisabeth Brambilla,Masayuki Noguchi,Andrew G. Nicholson,Kim R. Geisinger,Yasushi Yatabe,David G. Beer,Charles A. Powell,Gregory J. Riely,Paul Van Schil,Kavita Garg,John H. M. Austin,Hisao Asamura,Valerie W. Rusch,Fred R. Hirsch,Giorgio V. Scagliotti,Tetsuya Mitsudomi,Rudolf M. Huber,Yuichi Ishikawa,James R. Jett,Montserrat Sanchez-Cespedes,Jean-Paul Sculier,Takashi Takahashi,Masahiro Tsuboi,Johan Vansteenkiste,Ignacio I. Wistuba,Pan-Chyr Yang,Denise R. Aberle,Christian Brambilla,Douglas B. Flieder,Wilbur A. Franklin,Adi F. Gazdar,Michael K. Gould,Philip S. Hasleton,Douglas W. Henderson,Bruce E. Johnson,David A Johnson,Keith M. Kerr,Keiko Kuriyama,Jin Soo Lee,Vincent A. Miller,Iver Petersen,Victor L. Roggli,Rafael Rosell,Nagahiro Saijo,Erik Thunnissen,M. Tsao,David Yankelewitz +47 more
TL;DR: This new adenocarcinoma classification is needed to provide uniform terminology and diagnostic criteria, especially for bronchioloalveolar carcinoma (BAC), the overall approach to small nonresection cancer specimens, and for multidisciplinary strategic management of tissue for molecular and immunohistochemical studies.
Journal ArticleDOI
The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.
Peter Goldstraw,Kari Chansky,John Crowley,Ramón Rami-Porta,Hisao Asamura,Wilfried Ernst Erich Eberhardt,Andrew G. Nicholson,Patti A. Groome,Alan Mitchell,Vanessa Bolejack,David Ball,David G. Beer,Ricardo Beyruti,Frank C. Detterbeck,Wilfried Eberhardt,John G. Edwards,Françoise Galateau-Salle,Dorothy Giroux,Fergus V. Gleeson,James Huang,Catherine Kennedy,Jhingook Kim,Young Tae Kim,Laura Kingsbury,Haruhiko Kondo,Mark Krasnik,Kaoru Kubota,Antoon Lerut,Gustavo Lyons,Mirella Marino,Edith M. Marom,Jan P. van Meerbeeck,Takashi Nakano,Anna K. Nowak,Michael D Peake,Thomas W. Rice,Kenneth E. Rosenzweig,Enrico Ruffini,Valerie W. Rusch,Nagahiro Saijo,Paul Van Schil,Jean-Paul Sculier,Lynn Shemanski,Kelly G. Stratton,Kenji Suzuki,Yuji Tachimori,Charles F. Thomas,William D. Travis,Ming-Sound Tsao,Andrew T. Turrisi,Johan Vansteenkiste,Hirokazu Watanabe,Yi-Long Wu,Paul Baas,Jeremy J. Erasmus,Seiki Hasegawa,Kouki Inai,Kemp H. Kernstine,Hedy L. Kindler,Lee M. Krug,Kristiaan Nackaerts,Harvey I. Pass,David C. Rice,Conrad Falkson,Pier Luigi Filosso,Giuseppe Giaccone,Kazuya Kondo,Marco Lucchi,Meinoshin Okumura,Eugene H. Blackstone,F. Abad Cavaco,E. Ansótegui Barrera,J. Abal Arca,I. Parente Lamelas,A. Arnau Obrer,R. Guijarro Jorge,D. Ball,G.K. Bascom,A. I. Blanco Orozco,M. A. González Castro,M.G. Blum,D. Chimondeguy,V. Cvijanovic,S. Defranchi,B. de Olaiz Navarro,I. Escobar Campuzano,I. Macía Vidueira,E. Fernández Araujo,F. Andreo García,Kwun M. Fong,G. Francisco Corral,S. Cerezo González,J. Freixinet Gilart,L. García Arangüena,S. García Barajas,P. Girard,Tuncay Göksel,M. T. González Budiño,G. González Casaurrán,J. A. Gullón Blanco,J. Hernández Hernández,H. Hernández Rodríguez,J. Herrero Collantes,M. Iglesias Heras,J. M. Izquierdo Elena,Erik Jakobsen,S. Kostas,P. León Atance,A. Núñez Ares,M. Liao,M. Losanovscky,G. Lyons,R. Magaroles,L. De Esteban Júlvez,M. Mariñán Gorospe,Brian C. McCaughan,Catherine J. Kennedy,R. Melchor Íñiguez,L. Miravet Sorribes,S. Naranjo Gozalo,C. Álvarez de Arriba,M. Núñez Delgado,J. Padilla Alarcón,J. C. Peñalver Cuesta,Jongsun Park,H. Pass,M. J. Pavón Fernández,Mara Rosenberg,Enrico Ruffini,V. Rusch,J. Sánchez de Cos Escuín,A. Saura Vinuesa,M. Serra Mitjans,Trond Eirik Strand,Dragan Subotic,S.G. Swisher,Ricardo Mingarini Terra,Charles R. Thomas,Kurt G. Tournoy,P. Van Schil,M. Velasquez,Y.L. Wu,K. Yokoi +142 more
TL;DR: The methods used to evaluate the resultant Stage groupings and the proposals put forward for the 8th edition of the TNM Classification for lung cancer due to be published late 2016 are described.
Journal ArticleDOI
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
Masahiro Fukuoka,Yi-Long Wu,Sumitra Thongprasert,Patrapim Sunpaweravong,Swan Swan Leong,Virote Sriuranpong,Tsu Yi Chao,Tsu Yi Chao,Kazuhiko Nakagawa,Da Tong Chu,Nagahiro Saijo,Emma Duffield,Yuri Rukazenkov,Georgina Speake,Haiyi Jiang,Alison Armour,Ka Fai To,James Chih-Hsin Yang,Tony Mok +18 more
TL;DR: EGFR mutations are the strongest predictive biomarker for PFS and tumor response to first-line gefitinib versus carboplatin/paclitaxel and the predictive value of EGFR gene copy number was driven by coexisting EGFR mutation (post hoc analysis).
Journal ArticleDOI
Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung Cancer
Kazumasa Noda,Yutaka Nishiwaki,Masaaki Kawahara,Shunichi Negoro,Takahiko Sugiura,A. Yokoyama,Masahiro Fukuoka,K. Mori,Koshiro Watanabe,Tomohide Tamura,Seiichiro Yamamoto,Nagahiro Saijo +11 more
TL;DR: Irinotecan plus cisplatin is an effective treatment for metastatic small-cell lung cancer and severe or life-threatening diarrhea was more frequent in the irinotican-plus-cisplatin group than in the etoposide-plus -cis Platin group.